Metastatic Colorectal Cancer: Management With Trifluridine/Tipiracil

RECOMMENDED

Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib

Clin Colorectal Cancer.

Unseld M, Drimmel M, Siebenhüner A, Gleiss A, Bianconi D, Kieler M, Scheithauer W, Winder T, Prager GW

doi: 10.1016/j.clcc.2018.05.012.

Gastrointestinal Cancer

Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison

Clin Colorectal Cancer.

Masuishi T, Taniguchi H, Hamauchi S, Komori A, Kito Y, Narita Y, Tsushima T, Ishihara M, Todaka A, Tanaka T, Yokota T, Kadowaki S, Machida N, Ura T, Fukutomi A, Ando M, Onozawa Y, Tajika M, Yasui H, Muro K, Mori K, Yamazaki K

doi: 10.1016/j.clcc.2016.07.019.

Gastrointestinal Cancer

Trifluridine/Tipiracil plus Bevacizumab in Patients with Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy: the Randomized TASCO1 Study

Ann Oncol.

Van Cutsem E, Danielewicz I, Saunders MP, Pfeiffer P, Argilés G, Borg C, Glynne-Jones R, Punt CJA, Van de Wouw AJ, Fedyanin M, Stroyakovskiy D, Kroening H, Garcia-Alfonso P, Wasan H, Falcone A, Kanehisa A, Egorov A, Aubel P, Amellal N, Moiseenko V

doi: 10.1016/j.annonc.

Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution

Clin Colorectal Cancer.

Kotani D, Shitara K, Kawazoe A, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T.

doi: 10.1016/j.clcc.2015.11.005.

Gastrointestinal Cancer

Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients

J Clin Med.

Unseld M, Fischöder S, Jachs M, Drimmel M, Siebenhüner A, Bianconi D, Kieler M, Puhr H, Minichsdorfer C, Winder T, Prager GW

doi: 10.3390/jcm9061772.

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Gastrointestinal Cancer

Practical considerations in the use of regorafenib in metastatic colorectal cancer

Ther Adv Med Oncol.

Loupakis F, Antonuzzo L, Bachet JB, Kuan FC, Macarulla T, Pietrantonio F, Xu RH, Taniguchi H, Winder T, Yuki S, Zeng S, Bekaii-Saab T

doi: 10.1177/1758835920956862.

ASCO^® 2019

Gastrointestinal Cancer

Colorectal Cancer

Oki et al. 2019. Trifluridine/tipiracil plus bevacizumab in elderly patients with previously untreated metastatic colorectal cancer (KSCC1602): A multicenter, phase II clinical trial. Oral presentation presented at: ASCO 2019 Congress; May 31–June 4; Chicago, IL, USA.

Gastrointestinal Cancer

Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer

JAMA Oncol.

Mackintosh C, Yuan C, Ou FS, Zhang S, Niedzwiecki D, Chang IW, O'Neil BH, Mullen BC, Lenz HJ, Blanke CD, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg RM, O'Reilly EM, Meyerhardt JA, Ng K

doi: 10.1001/jamaoncol.2020.3938.

Related content

Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib

Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison

Trifluridine/Tipiracil plus Bevacizumab in Patients with Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy: the Randomized TASCO1 Study

Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution

Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients

Recent Developments in Metastatic Breast Cancer

Practical considerations in the use of regorafenib in metastatic colorectal cancer

Colorectal Cancer

Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer